Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Predictors of outcomes to allogeneic hematopoietic cell transplantation (allo-HCT) for TP53 mutant myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) patients and impact of hypomethylating agent (HMA) maintenance therapy
Predictors of outcomes to allogeneic hematopoietic cell transplantation (allo-HCT) for TP53 mutant myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) patients and impact of hypomethylating agent (HMA) maintenance therapy Wagstaff, C., Mishra, A., McLemore, A., Chan, O., Shallis, R., Pidala, J., Kuykendall, A., Reynolds, S., Elmariah, H., Al Ali, N., Torres, N., Xie, Z., Perez, L., Faramand, R., Walker, A., Nishihori, T., Padron, E., Lancet, J., Bejanyan, N., Komrokji, R., Sallman, D. ELSEVIER. 2025View details for DOI 10.1182/blood-2025-4291
View details for Web of Science ID 001663645800041